Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
sales@csnpharm.com
DUB
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN13933 | VLX1570 | 1431280-51-1 | VLX1570 is a deubiquitinylating enzyme DUB competitive inhibitor with an IC50 of approximately 10M in vitro and shows coinhibition of the deubiquitinating enzymes like USP14 and UCHL5 |
| CSN17621 | USP7-USP47 Inhibitor | 1247825-37-1 | USP7-USP47 inhibitor is a potent and dual inhibitor of USP7USP47 with IC50s of 042 M USP7 and 10 M USP47 |
| CSN17772 | USP7-IN-1 | 1381291-36-6 | USP7-IN-1 is a selective and reversible inhibitor of USP7 with IC50 of 33 M showing less or no inhibition on USP5 USP8 Uch-L1 Uch-L3 and Caspase IC50 200 M For HCT116 cell the viability GI50 is 67 M |
| CSN19439 | TCID | 30675-13-9 | TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 06 M 125-fold selective to L1 |
| CSN18929 | SJB3-019A | 2070015-29-9 | SJB3-019A is a potent USP1 inhibitor 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 00781 M |
| CSN16328 | SJB2-043 | 63388-44-3 | SJB2-043 is an inhibitor of ubiquitin-specific protease 1 USP1 and it is one of derivatives of C527 |
| CSN13807 | PR-619 | 2645-32-1 | PR-619 is a broad-spectrum and reversible inhibitor of the deubiquitinylating enzymes DUBs with EC50 of 1-20 M and it was developed for chemotherapy |
| CSN13634 | P22077 | 1247819-59-5 | P22077 is an inhibitor of ubiquitin specific protease USP7 EC50 86 M P22077 also inhibits the deubiquitinase USP47 |
| CSN16620 | P005091 | 882257-11-6 | P005091 acts as a selective inhibitor of ubiquitin-specific protease 7 USP7 and USP47 with the EC50s of 42 M and 43 M respectively |
| CSN18918 | NSC 632839 HCl | 157654-67-6 | NSC 632839 hydrochloride is an nonselective inhibitor of isopeptidase and inhibits various proteins including USP2 USP7 and SENP2 EC50 45 4 M 37 1 M and 98 18 M respectively |
| CSN18920 | ML364 | 1991986-30-1 | ML364 is an USP2 inhibitor |
| CSN15929 | ML323 | 1572414-83-5 | ML323 exhibits reversible inhibition of USP1-UAF1 with IC50 of 76 nM and it also inhibits deneddylase and deSUMOylase |
| CSN18381 | LDN-57444 | 668467-91-2 | LDN-57444 is a reversible inhibitor of UCHL1 with IC50 of 088 M Ki 04 M and its selectivity is better than UCH-L3 IC50 25 M |
| CSN17834 | HBX 19818 | 1426944-49-1 | HBX 19818 is a selective USP7 inhibitor with IC50 of 281 M |
| CSN23352 | GNE-6776 | 2009273-71-4 | GNE-6776 is selective ubiquitin specific protease-7 USP7 inhibitor with IC50 of 134 M through binding to acidic amino acid residues |
| CSN23348 | GNE-6640 | 2009273-67-8 | GNE-6640 is a selective inhibitor of ubiquitin specific protease-7 USP7 IC50 075 M that can induce tumor cell death and enhance the effect of chemotherapy drugs |
| CSN22406 | FT827 | 1959537-86-0 | FT827 is a selective and covalent ubiquitin-specific protease 7 USP7 inhibitor with an IC50 of 52 nM |
| CSN21254 | FT671 | 1959551-26-8 | FT671 is a potent and selective USP7 inhibitor with an IC50 of 52 nM and binds to the USP7 catalytic domain with a Kd of 65 nM |
| CSN18587 | DUBs-IN-3 | 924296-17-3 | DUBs-IN-3 is a potent deubiquitinase enzyme inhibitor with IC50s of 31 M for USP8 showing 30 fold selectivity over USP7 IC50 100 M |
| CSN18589 | DUBs-IN-2 | 924296-19-5 | DUBs-IN-2 is a potent deubiquitinase enzyme inhibitor with IC50s of 72 M093 M for USP7USP8 respectively |
| CSN18588 | DUBs-IN-1 | 924296-18-4 | DUBs-IN-1 is a potent deubiquitinase enzyme inhibitor with IC50s of 18 M071 M for USP7USP8 respectively |
| CSN21377 | C527 | 192718-06-2 | C527 is a is a pan DUB enzyme inhibitor with a high potency for the USP1UAF1 complex IC50088 M |
| CSN15845 | b-AP15 | 1009817-63-3 | b-AP15 is an inhibitor of the ubiquitin carboxyl-terminal hydrolase isozyme L5 UCHL5 and ubiquitin-specific-processing protease 14 USP14 In purified 19S proteasomes b-AP15 can inhibit DUB activity with an IC50 of 21 M |
| CSN10355 | Auranofin | 34031-32-8 | Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-B activation, Auranofin can attenuats the cardiac hypertrophy. |
| CSN22847 | HBX 41108 | 924296-39-9 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
